近日,亚盛医药宣布BTK降解剂APG-3288的新药临床申请(IND)获美国FDA许可,将开展其治疗复发/难治B细胞恶性肿瘤的临床研究。该研究是一项全球多中心、开放性的I期临床研究,旨在评估APG-3288治疗复发/难治性血液系统恶性肿瘤患者的安全性、耐受性、PK特征及初步疗效。APG-3288临床获批,标志着亚盛医药在靶向蛋白降解领域的研发成果已正式进入临床阶段,同时也是其全球创新管线的又一重大...
Source Link近日,亚盛医药宣布BTK降解剂APG-3288的新药临床申请(IND)获美国FDA许可,将开展其治疗复发/难治B细胞恶性肿瘤的临床研究。该研究是一项全球多中心、开放性的I期临床研究,旨在评估APG-3288治疗复发/难治性血液系统恶性肿瘤患者的安全性、耐受性、PK特征及初步疗效。APG-3288临床获批,标志着亚盛医药在靶向蛋白降解领域的研发成果已正式进入临床阶段,同时也是其全球创新管线的又一重大...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.